HIV-1感染者单核细胞亚群中人免疫球蛋白样受体亚家族B成员2与免疫重建不良免疫表型的相关性研究  

Correlation between LILRB2 in monocyte subgroups of HIV-1 patients and the immune phenotype of poor immune reconstruction

作　　者：白若靖 代丽丽 Bai Ruojing;Dai Lili(Department of Geriatrics,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing 102218,China;Infection Center Travel Clinic,Beijing You′an Hospital Affiliated to Capital Medical University,Beijing 100069,China)

机构地区：[1]清华大学临床医学院,清华大学附属北京清华长庚医院老年医学科,北京102218 [2]首都医科大学附属北京佑安医院感染中心旅行门诊,北京100069

出　　处：《中华微生物学和免疫学杂志》2024年第11期935-942,共8页Chinese Journal of Microbiology and Immunology

基　　金：国家自然科学基金(82272320);北京市自然科学基金(7222092)。

摘　　要：目的探究不同HIV-1感染者单核细胞亚群中人免疫球蛋白样受体亚家族B成员2(leukocyte immunoglobulin-like receptor subfamily B member 2,LILRB2)与免疫表面相关分子的共表达,分析LILRB2与HIV-1感染免疫重建不良者的相关性。方法选取2021年1月—2022年9月,在北京佑安医院感染中心就诊的男男性行为人群(men who have sex with men,MSM)慢性HIV-1感染者为研究对象,将其分为健康对照组(healthy controls,HCs组,n=22)、慢性HIV-1感染且未接受抗病毒治疗组(treatment-naïve patients,TNs组,n=22)、免疫重建良好组(immune responders,IRs组,n=22)和免疫重建不良组(immune non-responders,INRs组,n=22)。流式细胞术检测各组经典型(CD14^(++)CD16-)、中间型(CD14^(++)CD16^(+))、非经典型(CD14^(+)CD16^(++))单核细胞亚群中LILRB2的表达比例,及其与免疫分子CD80、CD86、CD163、人类白细胞DR抗原(HLA-DR)和PD-L1的共表达情况,组间比较采用Kruskal-Wallis检验,然后采用Dunn多重比较进行统计分析。结果INRs组CD14^(+)CD16^(++)单核细胞亚群LILRB2的表达水平显著高于IRs组(P<0.05)、TNs组(P<0.05)和HCs组(P<0.001)。TNs组CD14^(+)CD16^(++)单核细胞LILRB2和CD80的共表达水平显著高于HCs组(P<0.001)、IRs组(P<0.01)和INRs组(P<0.001)。INRs组CD14^(+)CD16^(++)单核细胞亚群LILRB2和CD86的共表达水平显著高于HCs组(P=0.001)、TNs组(P<0.05)和IRs组(P<0.05)。各组CD14^(++)CD16^(+)单核细胞LILRB2和CD163的共表达差异最为显著,其中INRs组显著低于IRs组(P<0.01)和HCs组(P<0.01)。在CD14^(+)CD16^(++)单核细胞中,INRs组和TNs组的HLA-DR和LILRB2共表达情况相近,均显著高于HCs组(P<0.01,P<0.05)。结论LILRB2与HIV-1感染者的单核细胞异常活化有关,其在单核亚群中的表达变化与免疫重建不良的发生存在潜在关联。Objective To investigate the co-expression of leukocyte immunoglobulin-like receptor subfamily B member 2(LILRB2)and immune surface-related molecules in different monocyte subgroups of HIV-1 patients,and analyze the correlation between LILRB2 and poor immune reconstruction in HIV-1 infection.Methods Men who have sex with men(MSM)with chronic HIV-1 infection presenting to the Infection Center of Beijing You′an Hospital from January 2021 to September 2022 were enrolled in this study.They were categorized into four groups:healthy controls(HCs,n=22),treatment-naive patients(TNs,n=22),immune responders(IRs,n=22),and immune non-responders(INRs,n=22).Flow cytometry was used to analyze LILRB2 expression in classical(CD14^(++)CD16-),intermediate(CD14^(++)CD16^(+)),and non-classical(CD14^(+)CD16^(++))monocyte subsets,and the co-expression of LILRB2 with CD80,CD86,CD163,human leukocyte antigen-DR(HLA-DR),and PD-L1.Kruskal-Wallis test and Dunn′s post-hoc analysis were used for statistical analysis.Results The expression of LILRB2 in CD14^(+)CD16^(++)monocytes increased significantly in the INRs group as compared with that in the IRs group(P<0.05),the TNs group(P<0.05),and the HCs group(P<0.001).Additionally,the co-expression of LILRB2 and CD80 on CD14^(+)CD16^(++)monocytes increased significantly in the TNs group than that in the HCs group(P<0.001),the IRs group(P<0.01),and the INRs group(P<0.001);the co-expression of LILRB2 and CD86 on CD14^(+)CD16^(++)monocyte subsets was enhanced in the INRs group than in the HCs group(P=0.001),the TNs group(P<0.05),and the IRs group(P<0.05);the co-expression of LILRB2 and CD163 on CD14^(++)CD16^(+)monocytes represented the most significant variation among the groups,with the INRs group exhibiting significantly lower level compared to both the IRs group(P<0.01)and the HCs group(P<0.01).In contrast,the co-expression of HLA-DR and LILRB2 on CD14^(+)CD16^(++)monocytes was comparable between the INRs and the TNs groups,yet significantly elevated as compared with that in the HCs group(P<0.

关 键 词：LILRB2 免疫重建不良 HIV-1 单核细胞亚群 

分 类 号：R512.91[医药卫生—内科学]